文献速递结核与非结核分枝杆菌

生物标志物指导的结核病预防性治疗:CORTIS随机对照试验

Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2021-01-25

CORTIS试验在南非五个社区招募2923名无HIV、无近期结核及合并症的成人,评估转录组标志物RISK11对 prevalent 和 incident 结核的判别能力及标志物指导的3HP(异烟肼+利福喷丁)预防治疗效果。

要点

  • RISK11可区分 prevalent 和 incident 结核风险,阳性者15个月结核累积概率显著高于阴性者。
  • 3HP相关严重不良事件包括1例癫痫住院(异烟肼意外过量)和1例原因不明死亡。

核心结论

  • RISK11标志物可区分 prevalent 结核或进展为 incident 结核的个体与保持健康者,但排除基线结核后对标志物阳性者提供3HP未减少15个月内进展为结核。

研究设计与样本

  • RISK11阳性者按1:2区组随机分配至每周一次直接观察下异烟肼+利福喷丁12周(n=375)或不治疗(n=764),另随机选取1784名RISK11阴性者不治疗。
  • 主要终点为微生物学确诊的肺结核,主动监测15个月,主要结局指标为RISK11阳性与阴性者结核风险比及治疗 efficacy。

主要发现

  • 3HP相关严重不良事件包括1例因癫痫住院(异烟肼意外过量)和1例原因不明死亡(可能时间相关)。

临床怎么用

  • RISK11目前不适用于指导预防性治疗决策,因标志物指导的3HP未显示减少结核进展。
  • 对RISK11阳性者仍需排除基线活动性结核,其 prevalent 结核风险显著增高。

局限性

  • 研究仅纳入无HIV、无近期结核及合并症的成人,外推至其他人群需谨慎。
  • 3HP疗效置信区间宽,不能排除具有临床意义的获益或危害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted preventive therapy for individuals at highest risk of incident tuberculosis might impact the epidemic by interrupting transmission. We tested performance of a transcriptomic signature of tuberculosis (RISK11) and efficacy of signature-guided preventive therapy in parallel, using a hybrid three-group study design. METHODS: Adult volunteers aged 18-59 years were recruited at five geographically distinct communities in South Africa. Whole blood was sampled for RISK11 by quantitative RT-PCR assay from eligible volunteers without HIV, recent previous tuberculosis (ie, <3 years before screening), or comorbidities at screening. RISK11-positive participants were block randomised (1:2; block size 15) to once-weekly, directly-observed, open-label isoniazid and rifapentine for 12 weeks (ie, RISK11 positive and 3HP positive), or no treatment (ie, RISK11 positive and 3HP negative). A subset of eligible RISK11-negative volunteers were randomly assigned to no treatment (ie, RISK11 negative and 3HP negative). Diagnostic discrimination of prevalent tuberculosis was tested in all participants at baseline. Thereafter, prognostic discrimination of incident tuberculosis was tested in the untreated RISK11-positive versus RISK11-negative groups, and treatment efficacy in the 3HP-treated versus untreated RISK11-positive groups, during active surveillance through 15 months. The primary endpoint was microbiologically confirmed pulmonary tuberculosis. The primary outcome measures were risk ratio [RR] for tuberculosis of RISK11-positive to RISK11-negative participants, and treatment efficacy. This trial is registered with ClinicalTrials.gov, NCT02735590. FINDINGS: 20 207 volunteers were screened, and 2923 participants were enrolled, including RISK11-positive participants randomly assigned to 3HP (n=375) or no 3HP (n=764), and 1784 RISK11-negative participants. Cumulative probability of prevalent or incident tuberculosis disease was 0·066 (95% CI 0·049 to 0·084) in RISK11-positive (3HP negative) participants and 0·018 (0·011 to 0·025) in RISK11-negative participants (RR 3·69, 95% CI 2·25-6·05) over 15 months. Tuberculosis prevalence was 47 (4·1%) of 1139 versus 14 (0·78%) of 1984 in RISK11-positive compared with RISK11-negative participants, respectively (diagnostic RR 5·13, 95% CI 2·93 to 9·43). Tuberculosis incidence over 15 months was 2·09 (95% CI 0·97 to 3·19) vs 0·80 (0·30 to 1·30) per 100 person years in RISK11-positive (3HP-negative) participants compared with RISK11-negative participants (cumulative incidence ratio 2·6, 95% CI 1·2 to 5·9). Serious adverse events related to 3HP included one hospitalisation for seizures (unintentional isoniazid overdose) and one death of unknown cause (possibly temporally related). Tuberculosis incidence over 15 months was 1·94 (95% CI 0·35 to 3·50) versus 2·09 (95% CI 0·97 to 3·19) per 100 person-years in 3HP-treated RISK11-positive participants compared with untreated RISK11-positive participants (efficacy 7·0%, 95% CI -145 to 65). INTERPRETATION: The RISK11 signature discriminated between individuals with prevalent tuberculosis, or progression to incident tuberculosis, and individuals who remained healthy, but provision of 3HP to signature-positive individuals after exclusion of baseline disease did not reduce progression to tuberculosis over 15 months. FUNDING: Bill and Melinda Gates Foundation, South African Medical Research Council.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021. PMID: 33508224. doi:10.1016/S1473-3099(20)30914-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。